Nebulisers comparison with inhaled tobramycin in young children with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 6, Issue 2, 2007, Pages 137-143

  Clavel, Aurélie ^a   Boulaméry, Audrey ^a   Bosdure, Emmanuelle ^a   Luc, Caroline ^a   Lanteaume, André ^b   Gorincour, Guillaume ^a   Stremler Lebel, Nathalie ^a   Sarles, Jacques ^a   Andrieu, Véronique ^b   Dubus, Jean Christophe ^a,b  

^a TIMONE HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Child; Cystic fibrosis; Nebulisation; Pulmonary deposition; Tobramycin

Indexed keywords

CREATININE; TOBRAMYCIN;

ARTICLE; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; CRYING; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EXCRETION; DRUG URINE LEVEL; FACE MASK; FEMALE; HUMAN; IMMUNOPRECIPITATION; INFANT; INTERMETHOD COMPARISON; MALE; NEBULIZER; PILOT STUDY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; STUDENT T TEST; URINARY EXCRETION;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INFANT; MALE; NEBULIZERS AND VAPORIZERS; PILOT PROJECTS; TOBRAMYCIN;

EID: 33947114560     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2006.06.002     Document Type: Article

References (24)

1. Vaincre la mucoviscidose. Résultats préliminaires du rapport sur la situation de la mucoviscidose en France en 2003. www.vaincrelamuco.org/publications/resultats_preliminaires_ONM2003.pdf.
2. Nixon G.M., Armstrong D.S., Carzino R., Carlin J.B., Olinsky A., Robertson C.F., et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 138 (2001) 699-704
3. Li Z., Kosorok M.R., Farrell P.M., Laxova A., West S.E., Green C.G., et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 293 (2005) 581-588
4. Maselli J.H., Sontag M.K., Norris J.M., MacKenzie T., Wagener J.S., and Accurso F.J. Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening. Pediatr Pulmonol 36 (2003) 257-262
5. Farrell P.M., Li Z., Kosorok M.R., Laxova A., Green C.G., Collins J., et al. Bronchopulmonary disease in children with cystic fibrosis after early or delayed diagnosis. Am J Respir Crit Care Med 168 (2003) 1100-1108
6. Wiesemann H.G., Steinkamp G., Ratjen F., Bauernfeind A., Przyklenk B., Doring G., et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 25 (1998) 88-92
7. Ratjen F., Doring G., and Nikolaizik W.H. Effects of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 358 (2001) 983-984
8. Gibson R.L., Emerson J., McNamara S., Burns J.L., Rosenfeld M., Yunker A., et al. Cystic Fibrosis Therapeutics Development Network Study Group. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 167 (2003) 841-849
9. De Benedictis F.M., and Selvaggio D. Use of inhaler devices in pediatric asthma. Paediatr Drugs 5 (2003) 629-638
10. Chua H.L., Collis G.G., Newbury A.M., Chan K., Bower G.D., Sly P.D., et al. The influence of age on aerosol deposition in children with cystic fibrosis. Eur J Respir 7 (1994) 2185-2191
11. Maloll J., Rattray S., Walker G., Cook D., and Robertson C.F. Aerosol deposition in infants with cystic fibrosis. Pediatr Pulmonol 21 (1996) 276-281
12. Cheer S.M., Waugh J., and Noble S. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs 63 (2003) 2501-2520
13. Rosenfeld M., and Gibson R. Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. J Pediatr 139 (2001) 572-577
14. Dubus J.C., Kammerl A., Stremler-Lebel N., Luc C., Mély L., Chazalette J.P., et al. Nébulisation et mucoviscidose: la pratique.... Arch Pediatr 11 (2004) 767 [abstract]
15. Vecellio None L., Grimbert D., Bordenave J., Benoit G., Furet Y., Fauroux B., et al. Residual gravimetric method to nebulizer output. J Aerosol Med 17 (2004) 63-71
16. Dequin P.F., Faurisson F., Lemarié E., Delatour F., Marchand S., Valat C., et al. Urinary excretion reflects lung deposition of aminoglycoside aerosols in cystic fibrosis. Eur Respir J 18 (2001) 316-322
17. Asmus M.J., Stewart B.A., Milavetz G., Teresi M.E., Han S.H., Wang D., et al. Tobramycin as a pharmacologic tracer to compare airway deposition from nebulizers. Pharmacotherapy 22 (2002) 557-563
18. Brasfield D., and Hicks G. Evaluation of scoring system of the chest radiography in cystic fibrosis. AJR 134 (1980) 1195-1198
19. Chrystyn H. Standards for bioequivalence of inhaled products. Clin Pharmacokinet 26 (1994) 1-6
20. Geller D.E., Rosenfeld M., and Waltz D.A. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest 123 (2003) 28-36
21. Le Brun P.P., Vinks A.A., Touw D.J., Hekelaar N., Mannes G.P., Brimicombe R.W., et al. Can tobramycin inhalation be improved with a jet nebuliser?. Ther Drug Monit 21 (1999) 618-624
22. Coates A.L., Allen P.D., MacNeish C.F., Ho S.L., and Lands L.C. Effect of size and disease on estimated deposition of drugs administered using jet nebulization in children with cystic fibrosis. Chest 119 (2001) 1123-1130
23. Amirav I., and Balanov I. Nebuliser hood compared to mask in wheezy infants: aerosol therapy without tears. Arch Dis Child 88 (2003) 719-723
24. Knoch M., and Keller M. The customised electric nebuliser: a new category of liquid aerosol drug delivery systems. Expert Opin Drug Deliv 2 (2005) 377-390